News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Astex Pharmaceuticals (ASTX) Announces Initiation of SGI-110 Phase 2 Trial in Advanced Hepatocellular Carcinoma (HCC) Patients



1/2/2013 9:15:23 AM

DUBLIN, Calif., Jan. 2, 2013 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, announced that it has initiated a Phase 2, open-label, single-arm, non-randomized clinical trial, evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib).

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES